FDA feedback received for head & neck cancer in CPS below 1
Filed with ASX · · 2 pages · English
Story so far
Earlier from Immutep
- Immutep Quarterly Activities Report Q4 FY25
- Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
- Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
- Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
- Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
Later from Immutep
- Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
- Appendix 4E & 2025 Full Year Statutory Accounts
- Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
- New investigator-initiated Phase II trial for Efti
- Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep